Results 171 to 180 of about 8,241,327 (286)

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

NORTH CAROLINA - API PROGRAM IN HUMAN RESOURCE DEVELOPMENT [PDF]

Labor and Human Capital,
Jones, E. Walton
core   +1 more source

Increasing opportunities for community input in harm reduction program development using iterative engagement. [PDF]

Harm Reduct J
Wagner NM, Carlson JA, Bean M, Wineland A, Blum J, Cardona SA, Covarrubias S, Kempe A, King AC, Huebschmann AG.   +9 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Competency-Based Transitional Support Program for Newly Graduated Nurses: A Program Development Study. [PDF]

J Nurs Res
Kwon HK, Kim S, Lee KY, Jung E, Lee E.
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Correction: Youth focused life skills training and counselling services program-An inter-sectoral initiative in India: Program development and preliminary analysis of factors affecting life skills. [PDF]

PLoS One
Sukumar GM, Banandur PS, Nagaraja SR, Shenoy AB, Shahane S, Shankar RG, Banavaram AA, Yekkar GS, Rajneesh S, Gopalkrishna G.   +9 more
europepmc   +1 more source

The Importance of Motivation to Older Adult Physical and Cognitive Exercise Program Development, Initiation, and Adherence. [PDF]

Front Aging, 2022
O'Neil-Pirozzi TM, Cattaneo G, Solana-Sánchez J, Gomes-Osman J, Pascual-Leone A.   +4 more
europepmc   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Specialist paediatric palliative care program development in the standard-of-care era. [PDF]

Paediatr Child Health
Lysecki DL, Callen J, Humphreys J, Sutherland K, van Halderen C, Van Meer S, Zuniga-Villanueva G.   +6 more
europepmc   +1 more source